PHASE IIB EFFICACY TRIAL OF MOSAIC HIV-1 VACCINE REGIMEN IN AFRICAN WOMEN: IMBOKODO
Imbokodo is the first trial evaluating clinical efficacy of a heterologous HIV-1 vaccine regimen consisting of an Ad26 vector (Ad26.Mos4.HIV) expressing mosaic Gag/Pol/Env antigens for broad HIV-1 clade coverage, and an aluminum-adjuvanted clade C gp140. This trial, conducted in women at high risk for HIV-1 in sub-Saharan Africa, is supported by preclinical and early phase…